Eliminating encephalitogenic T cells without undermining protective immunity

Journal of Immunology

Volumn 192, Issue 1, 2014, Pages 73-83

  McNally, Jonathan P ^a   Elfers, Eileen E ^a   Terrell, Catherine E ^a   Grunblatt, Eli ^a   Hildeman, David A ^a   Jordan, Michael B ^a   Katz, Jonathan D ^a,b  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; ETOPOSIDE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SELECTIVITY; EFFECTOR CELL; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; IMMUNOPROPHYLAXIS; LYMPHOCYTOPENIA; MEMORY T LYMPHOCYTE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RELAPSE; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION;

EID: 84891112902     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301891     Document Type: Article

References (56)

1. Prakash, R. S., E. M. Snook, J. M. Lewis, R. W. Motl, and A. F. Kramer. 2008. Cognitive impairments in relapsing-remitting multiple sclerosis: a meta-analysis. Mult. Scler. 14: 1250-1261.
2. Lublin, F. D., S. C. Reingold; National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. 1996. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 46: 907-911.
3. Frohman, E. M., M. K. Racke, and C. S. Raine. 2006. Multiple sclerosis - the plaque and its pathogenesis. N. Engl. J. Med. 354: 942-955.
4. Henderson, A. P., M. H. Barnett, J. D. Parratt, and J. W. Prineas. 2009. Multiple sclerosis: distribution of inflammatory cells in newly forming lesions. Ann. Neurol. 66: 739-753.
5. Paty, D. W., D. K. Li;UBC MS/MRI Study Group, and; IFNB Multiple Sclerosis Study Group. 1993. Interferon b-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 662-667.
6. Polman, C. H., P. W. O'Connor, E. Havrdova, M. Hutchinson, L. Kappos, D. H. Miller, J. T. Phillips, F. D. Lublin, G. Giovannoni, A. Wajgt, et al. 2006. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354: 899-910.
7. Miller, A. E., and R. W. Rhoades. 2012. Treatment of relapsing-remitting multiple sclerosis: current approaches and unmet needs. Curr. Opin. Neurol. 25 (Suppl.): S4-S10.
8. Billich, A., F. Bornancin, P. Dévay, D. Mechtcheriakova, N. Urtz, and T. Baumruker. 2003. Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J. Biol. Chem. 278: 47408-47415.
9. Horga, A., and X. Montalban. 2008. FTY720 (fingolimod) for relapsing multiple sclerosis. Expert Rev. Neurother. 8: 699-714.
10. Hartung, H., R. Gonsette, N. König, H. Kwiecinski, A. Guseo, S. P. Morrissey, and H. Krapf. 2002. Mitoxantrone in progressive multiple sclerosis: a placebocontrolled, double-blind, randomised, multicentre trial. Lancet 360: 2018-2025.
11. Martinelli Boneschi, F., L. Vacchi, M. Rovaris, R. Capra, and G. Comi. 2013. Mitoxantrone for multiple sclerosis. CochraneDatabase Syst. Rev. 5: CD002127.
12. Van Assche, G., M. Van Ranst, R. Sciot, B. Dubois, S. Vermeire, M. Noman, J. Verbeeck, K. Geboes, W. Robberecht, and P. Rutgeerts. 2005. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 353: 362-368.
13. Cohen, J. A., F. Barkhof, G. Comi, H. P. Hartung, B. O. Khatri, X. Montalban, J. Pelletier, R. Capra, P. Gallo, G. Izquierdo, et al. 2010. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362: 402-415.
14. Mullen, J. T., T. K. Vartanian, and M. B. Atkins. 2008. Melanoma complicating treatment with natalizumab for multiple sclerosis. N. Engl. J. Med. 358: 647-648.
15. Furtado, G. C., M. C. G. Marcondes, J. Tsai, A. Wensky, J. J. Lafaille, C. Furtado, and J. Latkowski. 2008. Swift entry of myelin-specific T lymphocytes into the central nervous system in spontaneous autoimmune encephalomyelitis. J. Immunol. 181: 4648-4655.
16. Penaranda, C., Q. Tang, and J. A. Bluestone. 2011. Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J. Immunol. 187: 2015-2022.
17. Zocher, M., P. A. Baeuerle, T. Dreier, and A. Iglesias. 2003. Specific depletion of autoreactive B lymphocytes by a recombinant fusion protein in vitro and in vivo. Int. Immunol. 15: 789-796.
18. Gold, R., C. Linington, and H. Lassmann. 2006. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129: 1953-1971.
19. Ben-Nun, A., H. Otmy, and I. R. Cohen. 1981. Genetic control of autoimmune encephalomyelitis and recognition of the critical nonapeptide moiety of myelin basic protein in guinea pigs are exerted through interaction of lymphocytes and macrophages. Eur. J. Immunol. 11: 311-316.
20. Edwards, C. M., B. S. Glisson, C. K. King, S. Smallwood-Kentro, and W. E. Ross. 1987. Etoposide-induced DNA cleavage in human leukemia cells. Cancer Chemother. Pharmacol. 20: 162-168.
21. van Maanen, J. M., J. Retèl, J. de Vries, and H. M. Pinedo. 1988. Mechanism of action of antitumor drug etoposide: a review. J. Natl. Cancer Inst. 80: 1526-1533.
22. Jordan, M. B., C. E. Allen, S. Weitzman, A. H. Filipovich, and K. L. McClain. 2011. How I treat hemophagocytic lymphohistiocytosis. Blood 118: 4041-4052.
23. Johnson, T. S., C. E. Terrell, S.H. Millen, J. D. Katz, D. A. Hildeman, and M. B. Jordan. 2013. Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis. J. Immunol. 192: 84-91.
24. Harlin, H., S. B. Reffey, C. S. Duckett, T. Lindsten, and C. B Thompson. 2001. Characterization of XIAP-deficient mice. Mol. Cell Biol. 21: 3604-3608.
25. Wood, L. J., L. M. Nail, N. A. Perrin, C. R. Elsea, A. Fischer, and B. J. Druker. 2006. The cancer chemotherapy drug etoposide (VP-16) induces proinflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy-related symptoms. Biol. Res. Nurs. 8: 157-169.
26. Wojciechowski, S., M. B. Jordan, Y. Zhu, J. White, A. J. Zajac, and D. A. Hildeman. 2006. Bim mediates apoptosis of CD127lo effector T cells and limits T cell memory. Eur. J. Immunol. 36: 1694-1706.
27. Hildeman, D., D. Yanez, K. Pederson, T. Havighurst, and D. Muller. 1997. Vaccination against persistent viral infection immunopathological disease. J. Virol. 71: 9672-9678.
28. Strait, R. T., S. C. Morris, and F. D. Finkelman. 2006. IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and FcgRIIb cross-linking. J. Clin. Invest. 116: 833-841.
29. Kerlero de Rosbo, N., I. Mendel, and A. Ben-Nun. 1995. Chronic relapsing experimental autoimmune encephalomyelitis with a delayed onset and an atypical clinical course, induced in PL/J mice by myelin oligodendrocyte glycoprotein (MOG)-derived peptide: preliminary analysis of MOG T cell epitopes. Eur. J. Immunol. 25: 985-993.
30. Sospedra, M., and R. Martin. 2005. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23: 683-747.
31. Park, H., Z. Li, X. O. Yang, S. H. Chang, R. Nurieva, Y. H. Wang, Y. Wang, L. Hood, Z. Zhu, Q. Tian, and C. Dong. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6: 1133-1141.
32. Harrington, L. E., R. D. Hatton, P. R. Mangan, H. Turner, T. L. Murphy, K. M. Murphy, and C. T. Weaver. 2005. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6: 1123-1132.
33. Hande, K. R. 1998. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur. J. Cancer 34: 1514-1521.
34. Brown, A. M., and D. E. McFarlin. 1981. Relapsing experimental allergic encephalomyelitis in the SJL/J mouse. Lab. Invest. 45: 278-284.
35. Tuohy, V. K., and R. P. Kinkel. 2000. Epitope spreading: a mechanism for progression of autoimmune disease. Arch. Immunol. Ther. Exp. 48: 347-351.
36. McMahon, E. J., S. L. Bailey, C. V. Castenada, H. Waldner, and S. D. Miller. 2005. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat. Med. 11: 335-339.
37. Wherry, E. J., S.-J. Ha, S. M. Kaech, W. N. Haining, S. Sarkar, V. Kalia, S. Subramaniam, J. N. Blattman, D. L. Barber, and R. Ahmed. 2007. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27: 670-684.
38. Kotturi, M. F., J. Botten, M. Maybeno, J. Sidney, J. Glenn, H.-H. Bui, C. Oseroff, S. Crotty, B. Peters, H. Grey, et al. 2010. Polyfunctional CD4+ T cell responses to a set of pathogenic arenaviruses provide broad population coverage. Immunome Res. 6: 4.
39. Moskophidis, D., F. Lechner, H. Pircher, and R. M. Zinkernagel. 1993. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 362: 758-761.
40. Moore, C. S., A. L. O. Hebb, M. M. Blanchard, C. E. Crocker, P. Liston, R. G. Korneluk, and G. S. Robertson. 2008. Increased X-linked inhibitor of apoptosis protein (XIAP) expression exacerbates experimental autoimmune encephalomyelitis (EAE). J. Neuroimmunol. 203: 79-93.
41. Wojciechowski, S., P. Tripathi, T. Bourdeau, L. Acero, H. L. Grimes, J. D. Katz, F. D. Finkelman, and D. A. Hildeman. 2007. Bim/Bcl-2 balance is critical for maintaining naive and memory T cell homeostasis. J. Exp. Med. 204: 1665-1675.
42. Grayson, J. M., A. E. Weant, B. C. Holbrook, and D. Hildeman. 2006. Role of Bim in regulating CD8+ T-cell responses during chronic viral infection. J. Virol. 80: 8627-8638.
43. Elyaman, W., P. Kivisäkk, J. Reddy, T. Chitnis, K. Raddassi, J. Imitola, E. Bradshaw, V. K. Kuchroo, H. Yagita, M. H. Sayegh, and S. J. Khoury. 2008. Distinct functions of autoreactive memory and effector CD4+ T cells in experimental autoimmune encephalomyelitis. Am. J. Pathol. 173: 411-422.
44. Moore, C. S., A. L. O. Hebb, and G. S. Robertson. 2008. Inhibitor of apoptosis protein (IAP) profiling in experimental autoimmune encephalomyelitis (EAE) implicates increased XIAP in T lymphocytes. J. Neuroimmunol. 193: 94-105.
45. Arva, N. C., T. R. Gopen, K. E. Talbott, L. E. Campbell, A. Chicas, D. E. White, G. L. Bond, A. J. Levine, and J. Bargonetti. 2005. A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J. Biol. Chem. 280: 26776-26787.
46. Smeenk, L., S. J. van Heeringen, M. Koeppel, B. Gilbert, E. Janssen-Megens, H. G. Stunnenberg, and M. Lohrum. 2011. Role of p53 serine 46 in p53 target gene regulation. PLoS One 6: e17574.
47. Zall, H., A. Weber, R. Besch, N. Zantl, and G. Häcker. 2010. Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1. Mol. Cancer 9: 164.
48. Grandela, C., M. F. Pera, S. M. Grimmond, G. Kolle, and E. J. Wolvetang. 2007. p53 is required for etoposide-induced apoptosis of human embryonic stem cells. Stem Cell Res. 1: 116-128.
49. Terrell, C. E., and M. B. Jordan. 2013. Perforin deficiency impairs a critical immunoregulatory loop involving murine CD8+ T cells and dendritic cells. Blood 121: 5184-5191.
50. Küzelová, K., D. Grebënová, and B. Brodská. 2011. Dose-dependent effects of the caspase inhibitor Q-VD-OPh on different apoptosis-related processes. J. Cell. Biochem. 112: 3334-3342.
51. Degterev, A., J. Hitomi, M. Germscheid, I. L. Ch'en, O. Korkina, X. Teng, D. Abbott, G. D. Cuny, C. Yuan, G. Wagner, et al. 2008. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat. Chem. Biol. 4: 313-321.
52. Oh, U., G. Blevins, C. Griffith, N. Richert, D. Maric, C. R. Lee, H. McFarland, and S. Jacobson. 2009. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch. Neurol. 66: 471-479.
53. Imashuku, S. 2007. Etoposide-related secondary acute myeloid leukemia (t-AML) in hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 48: 121-123.
54. Oltersdorf, T., S. W. Elmore, A. R. Shoemaker, R. C. Armstrong, D. J. Augeri, B. A. Belli, M. Bruncko, T. L. Deckwerth, J. Dinges, P. J. Hajduk, et al. 2005. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-681.
55. Azmi, A. S., and R. M. Mohammad. 2009. Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J. Cell. Physiol. 218: 13-21.
56. Bardwell, P. D., J. Gu, D. McCarthy, C. Wallace, S. Bryant, C. Goess, S. Mathieu, C. Grinnell, J. Erickson, S. H. Rosenberg, et al. 2009. The Bcl-2 family antagonist ABT-737 significantly inhibits multiple animal models of autoimmunity. J. Immunol. 182: 7482-7489.